Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
QUCY · NASDAQ · Pharmaceutical Preparations
Quantum Cyber N.V. (QUCY) · oqro.io/stocks/QUCY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Quantum Cyber N.V. is on record in SEC filings since 2006.
No open-market sale by an insider of Quantum Cyber N.V. (QUCY) was filed with the SEC in the last 90 days.
No trade in Quantum Cyber N.V. (QUCY) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.512−0.04 (−7.25%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−32.5% (−$0.2464) from Mar 12, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $0.7584 on Mar 12, 2026 to $0.512 on Nov 20, 2026 (−32.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Mainz.
Last 12 months
Not enough history
Market value
$54.4M
Short interest: 789K shares sold short (0.7% of shares outstanding), −36.8% vs the previous count, 2.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$537K
−39.9% vs the year before
Net income, fiscal 2025
−$16.2M
A loss for the year
Shares outstanding
87.2M
As of Nov 12, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“O’Rourke resigned as a member of the Board and from his role as President of Quantum Drones Corporation, a wholly owned subsidiary of the Company (“Quantum Drones”), effective immediately.”
8-K on sec.govChanged auditor
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
No Schedule 13D or 13G filing on QUCY over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
We develop and sell in-vitro diagnostic (“IVD”) tests for the early detection of cancer. Throughout our 2025 fiscal year, our legacy ColoAlert product was marketed and sold in European markets. Since 2020, we have been developing both a blood and stool test for the early detection of pancreatic cancer. From 2022 to February 2026, we were developing our next generation colorectal cancer screening product, with the intention to launch these products in the future in the United States and in Europe. In February 2026, the Board made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business.
And 14 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 31, 2026. Read the filing
The risk factor headings of this report could not be read with confidence, so none are shown. They are in the filing.
On March 22, 2024, the Company filed a complaint in the Supreme Court of the State of New York against Boustead Securities, LLC, for breach of contract, unjust enrichment, and a declaratory judgment. Several weeks later, Boustead brought an arbitration against Mainz seeking to collect alleged unpaid compensation for financial services plus shares and warrants pursuant to two agreements.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Revenue
$967K
Free cash flow, last 12 months
−$16M
This quarter −$4.26M, a year earlier −$2.65M
Net debt
—
Debt —, cash $4.9M, at Sep 30, 2026
Net income, last 12 months
−$26.3M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.
Off-exchange trading: 62.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.3% on ATS, 57.0% with other brokers), above its 26-week average of 56.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (22.1%), INTELLIGENT CROSS LLC (12.6%), SIGMA X2 (12.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind